LFB Biotechnologies, SAS Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Framingham MA United States (1993)
Status: No NME R&D (1993)

Organization Overview

First Clinical Trial
2002
NCT00056550
First Marketed Drug
2009
antithrombin (Recombinant) (ATryn)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

LFB BIOMEDICAMENTS | LFB USA, Inc. | rEVO Biologics | rEVO Biologics, Inc.

Active Ingredients

Marketed Drugs (1)

antithrombin (Recombinant) (ATryn) (2009)

Drugs in Phase 4 Trials (2)

antithrombin iii (human) (thrombate iii) (7 trials)

coagulation factor viia (recombinant) (NovoSevenRT) (5 trials)

Drugs in Phase 3 Trials (1)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (3)

cαstx1 (1 trial)

cαstx2 (1 trial)

von Willebrand factor (Wilate) (1 trial)

Drugs in Phase 1 Trials (1)

heparin (liquaemin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Antithrombin III Deficiency (Phase 4)

Bacterial Infections (Phase 2)

Hemophilia A (Phase 3)

Hemophilia B (Phase 3)

Hemorrhage (Phase 1)

Infections (Phase 2)

Postoperative Hemorrhage (Phase 1)

Pre-Eclampsia (Phase 3)

Thrombophilia (Phase 4)

Thrombosis (Phase 3)

Venous Thrombosis (Phase 3)

von Willebrand Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 7